title: Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability.
abstract: Transport of IL-6 in blood is fundamental to the biology of this cytokine. In the present study, IL-6 transport, immunological reactivity, and biological availability were investigated in blood from melanoma patients subjected to different active specific immunization regimens (an anti-idiotypic mAb immunization protocol (mAb-keyhole limpet hemocyanin (KLH)-Calmette-Guerin bacillus (BCG), an autologous anti-cancer vaccine protocol (AAAP), or both). Sera were subjected to Sephadex G-200 gel filtration chromatography, and the structure and biological activity of IL-6 complexes in the eluate fractions were probed using five IL-6 ELISAs and two bioassays. Sera from patients administered mAb-KLH+BCG followed by AAAP contained three distinct classes of IL-6 eluting at 30, 200, and 450 kDa, each with its characteristic ELISA reactivity and bioactivity: the 30- and 450-kDa complexes were bioactive in the B9 and Hep3B assays, but the 200-kDa complex was not. The 30- and 450-kDa IL-6 complexes were preferentially reactive in the 7IL6/5IL6 ELISA, the 200-kDa IL-6 complexes were preferentially reactive in the 4IL6/5IL6 ELISA, while the three commercial ELISAs (R&D, Endogen, and Genzyme) detected essentially only the 30-kDa IL-6. In contrast, 1) sera from AAAP patients contained biologically active 30- and 450-kDa IL-6 complexes, while 2) sera from mAb-KLH+BCG patients contained 200-kDa IL-6 complexes inactive in ex vivo bioassays. Both the 450- and 200-kDa complexes included soluble IL-6R, with the 200-kDa complexes additionally containing ligand-occupied anti-IL-6 and anti-soluble IL-6R IgG. The data indicate the existence of specific mechanisms that regulate the transport and function of IL-6 in vivo.
authors.affiliation: Department of Cell Biology and Anatomy, New York Medical College, Valhalla 10514, USA.
authors.forename: M I
authors.initials: MI
authors.lastname: Ndubuisi
authors.forename: K
authors.initials: K
authors.lastname: Patel
authors.forename: R J
authors.initials: RJ
authors.lastname: Rayanade
authors.forename: A
authors.initials: A
authors.lastname: Mittelman
authors.forename: L T
authors.initials: LT
authors.lastname: May
authors.forename: P B
authors.initials: PB
authors.lastname: Sehgal
mesh_terms: D000912:Antibodies, Neoplasm / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D001682:Biological Availability; D001692:Biological Transport; D006801:Humans; D007167:Immunotherapy; D015850:Interleukin-6 / Q000097:blood* / Q000737:chemistry / Q000276:immunology; D008545:Melanoma / Q000097:blood / Q000628:therapy; D018832:Molecular Chaperones; D008970:Molecular Weight; D011485:Protein Binding; D019947:Receptors, Interleukin-6 / Q000097:blood
chemical_list: D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D015850:Interleukin-6; D018832:Molecular Chaperones; D019947:Receptors, Interleukin-6